MA55478A - Inhibiteurs bicycliques de hpk1 - Google Patents

Inhibiteurs bicycliques de hpk1

Info

Publication number
MA55478A
MA55478A MA055478A MA55478A MA55478A MA 55478 A MA55478 A MA 55478A MA 055478 A MA055478 A MA 055478A MA 55478 A MA55478 A MA 55478A MA 55478 A MA55478 A MA 55478A
Authority
MA
Morocco
Prior art keywords
bicyclic
hpk1 inhibitors
hpk1
inhibitors
bicyclic hpk1
Prior art date
Application number
MA055478A
Other languages
English (en)
Inventor
Christophe Denis Pascal Adelinet
Sophie Coupa
James Patrick Edwards
Laurence Anne Mevellec
Jorge Eduardo Vialard
Berthold Wroblowski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55478A publication Critical patent/MA55478A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055478A 2019-03-26 2020-03-24 Inhibiteurs bicycliques de hpk1 MA55478A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962823712P 2019-03-26 2019-03-26
EP19167828 2019-04-08

Publications (1)

Publication Number Publication Date
MA55478A true MA55478A (fr) 2022-02-09

Family

ID=69845448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055478A MA55478A (fr) 2019-03-26 2020-03-24 Inhibiteurs bicycliques de hpk1

Country Status (8)

Country Link
US (1) US12486264B2 (fr)
EP (1) EP3947373B1 (fr)
AU (1) AU2020249397C1 (fr)
CA (1) CA3129772A1 (fr)
ES (1) ES3031241T3 (fr)
MA (1) MA55478A (fr)
TW (1) TW202102500A (fr)
WO (1) WO2020193512A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (fr) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
EP4371987B9 (fr) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20240182465A1 (en) * 2021-03-03 2024-06-06 Genfleet Therapeutics (Shanghai) Inc. Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
KR20240007181A (ko) * 2021-05-11 2024-01-16 에보포인트 바이오사이언시스 컴퍼니 리미티드 질소 함유 헤테로고리 화합물
CN115490686A (zh) * 2021-06-18 2022-12-20 苏州信诺维医药科技股份有限公司 一类含氮杂环化合物
WO2023001794A1 (fr) 2021-07-20 2023-01-26 Astrazeneca Ab Pyrazine-2-carboxamides substituées utilisées en tant qu'inhibiteurs de hpk1 pour le traitement du cancer
CN113861188B (zh) * 2021-08-23 2023-02-28 杭州医学院 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用
US20250011319A1 (en) * 2021-10-15 2025-01-09 Lomond Therapeutics, Inc. SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
CN119060034B (zh) * 2024-09-02 2026-03-24 上海信诺维生物医药有限公司 一种含吡喃取代的吗啉类化合物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227337A1 (fr) 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Procédés et compositions de traitement du cancer à l'aide d'antagonistes de l'axe pd-1 et d'antagonistes de hpk1
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) * 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018081531A2 (fr) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Méthodess d'activation de lymphocytes t humains
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
EP3596075B1 (fr) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles utilisés en tant qu'inhibiteurs de hpk1
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
WO2018215668A1 (fr) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Nouveaux inhibiteurs de map4k1
WO2018228925A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
EP3638669A1 (fr) 2017-06-13 2020-04-22 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
WO2018228923A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués utilisés en tant que modulateurs de map4k1 pour le traitement de maladies cancéreuses
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof

Also Published As

Publication number Publication date
EP3947373B1 (fr) 2025-05-14
CA3129772A1 (fr) 2020-10-01
AU2020249397C1 (en) 2025-08-07
WO2020193512A1 (fr) 2020-10-01
AU2020249397A1 (en) 2021-09-30
AU2020249397B2 (en) 2025-04-17
EP3947373A1 (fr) 2022-02-09
US12486264B2 (en) 2025-12-02
EP3947373C0 (fr) 2025-05-14
ES3031241T3 (en) 2025-07-07
TW202102500A (zh) 2021-01-16
US20220169644A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
DK3956033T3 (da) Bicykliske forbindelser
IL282535A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
EP3947373C0 (fr) Inhibiteurs de hpk1 bicycliques
EP4007756C0 (fr) Inhibiteurs de kif18a
DK3740479T3 (da) Dna-pk-hæmmere
EP3843714A4 (fr) Inhibiteurs de cd73
EP3801503A4 (fr) Inhibiteurs de sarm1
EP3833350A4 (fr) Inhibiteurs de pyrrolopyrimidine itk
MA55477A (fr) Inhibiteurs de hpk1
MA52413A (fr) Inhibiteurs de cd73
MA55909A (fr) Inhibiteurs de cdk
MA52813A (fr) Inhibiteurs de sarm1
EP3980011C0 (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
EP3856176A4 (fr) Inhibiteurs de vap-1
EP3787635A4 (fr) Inhibiteurs de cd73
MA47301A (fr) Inhibiteurs sélectifs de jak1
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
EP3999517A4 (fr) Inhibiteurs de cd73
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3938358A4 (fr) Inhibiteurs de rad51